disufenton sodium has been researched along with Disease Models, Animal in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (83.33) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Q; Cheng, W; Du, X; Ewert, DL; Huang, X; Kopke, RD; Li, W; Lu, J; Nakmali, D; West, MB | 1 |
| Cheng, W; Du, X; Ewert, DL; Floyd, RA; Kopke, RD; Li, W; Saunders, D; Towner, RA; West, MB | 1 |
| Savitz, SI | 2 |
| Benatar, M; Fisher, M; Philip, M; Savitz, SI | 1 |
| Bath, AJ; Bath, PM; Buchan, A; Gray, LJ; Green, AR; Miyata, T | 1 |
| Bath, PM; Green, AR; Macleod, MR | 1 |
| Arba, F; Balami, JS; Buchan, AM; Kleinschnitz, C; Minnerup, J; Sutherland, BA | 1 |
| Buchan, AM; Kleinschnitz, C; Minnerup, J; Sutherland, BA | 1 |
| Marshall, JW; Ridley, RM | 1 |
| Green, AR; Marshall, JW; Ridley, RM | 1 |
| Bowes, LJ; Cummings, RM; Green, AR; Marshall, JW; Ridley, RM | 1 |
| Jauch, EC; Wagner, KR | 1 |
| Green, AR; Shuaib, A | 1 |
| Buchan, AM; Papadakis, M | 1 |
| Bhuiyan, N; Green, AR; Hainsworth, AH | 1 |
| Araujo, DM; Lapchak, PA | 1 |
| Donnan, GA | 1 |
| Rogalewski, A; Schäbitz, WR | 1 |
| Duffin, KJ; Green, AR; Marshall, JW; Ridley, RM | 1 |
| Corbett, D; Del Bigio, MR; Green, AR; Jackson, DM; Peeling, J | 1 |
| Borelli, AR; Cross, AJ; Green, AR; Sydserff, SG | 1 |
| Araujo, DM; Lapchak, PA; Song, D; Wei, J; Zivin, JA | 1 |
| Araujo, DM; Lapchak, PA; Purdy, R; Song, D; Wei, J; Zivin, JA | 1 |
9 review(s) available for disufenton sodium and Disease Models, Animal
| Article | Year |
|---|---|
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Humans; Neuroprotective Agents; Research; Research Design; Risk; Stroke | 2009 |
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.
Topics: Animals; Benzenesulfonates; Brain; Callithrix; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Male; Mice; Neuroprotective Agents; Random Allocation; Rats; Stroke | 2009 |
Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Chelating Agents; Clinical Trials as Topic; Combined Modality Therapy; Diffusion of Innovation; Disease Models, Animal; Drug Evaluation, Preclinical; Egtazic Acid; Hematopoietic Cell Growth Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnesium; Minocycline; NADPH Oxidases; Neuroprotective Agents; Pregnatrienes; Serum Albumin; Stroke; Thrombolytic Therapy; Translational Research, Biomedical | 2012 |
Neuroprotection for stroke: current status and future perspectives.
Topics: Animals; Antioxidants; Azoles; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; Humans; Hypothermia, Induced; Isoindoles; Neuroprotective Agents; Organoselenium Compounds; Stroke | 2012 |
Assessment of cognitive and motor deficits in a marmoset model of stroke.
Topics: Animals; Behavior, Animal; Benzenesulfonates; Callithrix; Chlormethiazole; Cognition; Disease Models, Animal; Female; Male; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Psychomotor Performance; Pyridines; Recovery of Function; Stroke | 2003 |
Therapeutic strategies for the treatment of stroke.
Topics: Animals; Benzenesulfonates; Cardiovascular Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Nitrogen Oxides; Stroke; Thrombolytic Therapy | 2006 |
Translational vehicles for neuroprotection.
Topics: Animals; Benzenesulfonates; Cerebral Hemorrhage; Disease Models, Animal; Humans; Neuroprotective Agents; Protein Biosynthesis; Stroke; Thrombolytic Therapy | 2006 |
A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke.
Topics: Animals; Benzenesulfonates; Cerebral Infarction; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Intracranial Embolism; Neuroprotective Agents; Reproducibility of Results; Research Design; Stroke | 2007 |
Advances in hemorrhagic stroke therapy: conventional and novel approaches.
Topics: Animals; Antihypertensive Agents; Antioxidants; Benzenesulfonates; Blood Pressure; Cardiovascular Agents; Coagulants; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Erythropoietin; Excitatory Amino Acid Antagonists; Factor VIIa; Hemostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Oxidative Stress; Signal Transduction; Stroke; Treatment Outcome | 2007 |
15 other study(ies) available for disufenton sodium and Disease Models, Animal
| Article | Year |
|---|---|
Electrophysiological assessment and pharmacological treatment of blast-induced tinnitus.
Topics: Acetylcysteine; Animals; Benzenesulfonates; Biomarkers; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Hair Cells, Auditory, Inner; Hearing Loss, Noise-Induced; Male; Rats; Tinnitus | 2021 |
Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury.
Topics: Acetylcysteine; Animals; Antioxidants; Benzenesulfonates; Blast Injuries; Brain Injuries, Traumatic; Cytoprotection; Disease Models, Animal; Hippocampus; Male; Neuroprotective Agents; Protein Aggregation, Pathological; Rats; Rats, Long-Evans; tau Proteins | 2016 |
Cosmic implications of NXY-059.
Topics: Animals; Benzenesulfonates; Disease Models, Animal; Humans; Neuroprotective Agents; Rats; Regional Blood Flow; Reproducibility of Results; Stroke | 2009 |
Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke.
Topics: Age Factors; Animals; Benzenesulfonates; Cardiovascular Agents; Data Interpretation, Statistical; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Humans; Multicenter Studies as Topic; Placebos; Random Allocation; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sex Factors; Stroke | 2009 |
Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures.
Topics: Animals; Behavior, Animal; Benzenesulfonates; Callithrix; Cerebral Cortex; Chlormethiazole; Disease Models, Animal; Drug Administration Routes; Evaluation Studies as Topic; Extinction, Psychological; Motor Activity; Neostriatum; Neuroprotective Agents; Nitrogen Oxides; Pyridines; Space Perception; Stereotaxic Techniques; Stroke; Time Factors | 2003 |
Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.
Topics: Animals; Benzenesulfonates; Callithrix; Disease Models, Animal; Drug Evaluation, Preclinical; Infarction, Middle Cerebral Artery; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Perceptual Disorders; Recovery of Function; Stroke; Time Factors; Treatment Outcome | 2003 |
Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies.
Topics: Acute Disease; Animals; Benzenesulfonates; Central Nervous System; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Humans; Hypothermia, Induced; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Stroke; Tenecteplase; Time Factors; Tissue Plasminogen Activator | 2004 |
The nitrone disodium 2,4-sulphophenyl-N-tert-butylnitrone is without cytoprotective effect on sodium nitroprusside-induced cell death in N1E-115 neuroblastoma cells in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Nucleus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electron Transport Complex II; Free Radical Scavengers; Hydrogen Peroxide; Mice; Mitochondria; Neuroblastoma; Neurons; Nitroprusside; Oxidants; Primates; Stroke | 2008 |
The 2007 Feinberg lecture: a new road map for neuroprotection.
Topics: Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Free Radical Scavengers; Humans; Neuroprotective Agents; Stroke | 2008 |
[Development of new stroke therapies: outlook for neuroprotective drugs].
Topics: Animals; Antioxidants; Benzenesulfonates; Brain; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation; Erythropoietin; Granulocyte Colony-Stimulating Factor; Humans; Magnetic Resonance Imaging; Neuroprotective Agents; Practice Guidelines as Topic; Stroke | 2008 |
NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.
Topics: Analysis of Variance; Animals; Arm; Behavior, Animal; Benzenesulfonates; Body Temperature; Brain; Brain Ischemia; Callithrix; Choice Behavior; Disease Models, Animal; Free Radical Scavengers; Hemodynamics; Infarction, Middle Cerebral Artery; Infusions, Intravenous; Kinesis; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Paresis; Perceptual Disorders | 2001 |
Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke.
Topics: Animals; Behavior, Animal; Benzenesulfonates; Blood Cell Count; Body Weight; Brain; Cell Death; Cerebral Hemorrhage; Disease Models, Animal; Free Radical Scavengers; Hematoma; Infusion Pumps; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Motor Skills; Neuroprotective Agents; Neutrophil Infiltration; Nitrogen Oxides; Pilot Projects; Rats; Rats, Sprague-Dawley; Stroke; Treatment Outcome | 2001 |
Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.
Topics: Administration, Cutaneous; Animals; Benzenesulfonates; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Infusion Pumps, Implantable; Ischemic Attack, Transient; Male; Neuroprotective Agents; Nitrogen Oxides; Rats; Rats, Inbred WKY | 2002 |
Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Topics: Animals; Behavior, Animal; Benzenesulfonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fibrinolytic Agents; Intracranial Embolism; Male; Microspheres; Neuroprotective Agents; Nitrogen Oxides; Rabbits; Spin Trapping; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2002 |
Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Topics: Animals; Benzenesulfonates; Blood Glucose; Body Temperature; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Fibrinolytic Agents; Intracranial Embolism; Male; Neuroprotective Agents; Nitrogen Oxides; Rabbits; Stroke; Tissue Plasminogen Activator; Treatment Outcome | 2002 |